CYTOTOXIC AGENTS/TARGETED CYTOTOXICS/CELL-CYCLE MODULATORS/APOPTOSIS INDUCERS/IMMUNOCONJUGATES
- Cell-cycle Modulators
- AG-024322
- AT7519
- R04584820
- Spindle Poisons
- BI 2536
- C242-DM4
- TPI-287
- TTI-237
- Other Cytotoxics/Apoptosis Inducers
- Azaspirane
- CB3304
- ES-285
- PM00104
- PT-523
- RH1
- RTA 401(CDDO) and RTA 402 (CDDO-Me)
- RTA 744 (WP774) and RTA 769
- S23906
- S-CKD602
- SJG-136
- ZIO-101
TARGETED AGENTS (REGULATORY AGENTS)/CYTOSTATICS/ANGIOGENESIS INHIBITORS
- Angiogenesis Inhibitors
- BIBF 1120
- CHIR258 (CHIR258LC)
- CP-868,596
- ENMD-1198
- OSI-930
- XL880
- Aurora Kinase Inhibitors
- AZD1152
- MK0457 (VX-680)
- MLN8054
- Epidermal Growth Factor Receptor (EGFr) Inhibitors
- ARRY-33454
- BIBW 2992
- XL647
- Heat-shock Protein 90 (Hsp90) Inhibitors
- CNF-1010
- IPI-504
- KOS-1022
- Other Targeted Therapeutics
- AGS-PSCA
- AZD6244 (ARRY-142886)
- GX15-070
- PD0325901
- PRO1762
- SPC2996
IMMUNOTHERAPEUTICS/VACCINES
- CHIR-12.12
- SGN-40
- TACI-Ig
LIST OF EXHIBITS
Exhibit 1 - Anticancer Agents in Phase I Monotherapy Clinical Trials with Recently Reported Preclinical or Clinical Findings
Exhibit 2 - Molecular Targets of Anticancer Agents in Phase I Monotherapy Clinical Trials
